AAV gene therapy
| 3 min read
A new platform combines engineered viral vectors with the brain's glymphatic system to improve gene delivery to glial cells implicated in multiple neurological disorders.
| 1 min read
Philip Wills, Chief Commercial Officer of the Cell & Gene Therapy Division at Catalent, reflects on how the gene therapy industry is evolving from early scientific breakthroughs to commercial maturity.
| 6 min read
Fit-for-purpose analytics like mass photometry give teams the confidence to refine processes before scaling to GMP-compliant production.
| 5 min read
With gene therapy now a clinical reality, innovators are designing delivery systems that can sustain lifelong correction, handle complex genes, and make treatments accessible to more patients.
| 5 min read
Emerging optogenetic, gene, and cell therapies are moving beyond single-gene treatments, offering hope for a broader range of patients with retinitis pigmentosa.
| 3 min read
These latest deals give Lilly a complementary portfolio of life-changing therapies and scalable gene therapy platforms.
| 4 min read
Another biotech retreats from AAV, a promising antibiotic, a paused CRISPR trial, and more led the news this week.
| 5 min read
After a decade of promise, AAV therapies are now confronting economic, clinical, and regulatory hurdles.
| 3 min read
Papzimeos is the first FDA-approved therapy for recurrent respiratory papillomatosis, a rare HPV-driven disease that has long forced patients into repeated surgeries.
| 2 min read
First commercially available cell culture solution for HEK293 cells and perfusion, optimized for high cell density, intensified processes and perfusion cultures.
